Estradiol phenylpropionate explained

Estradiol phenylpropionate (EPP), also known as estradiol 17β-phenylpropionate and sold under the brand name Menformon Prolongatum, is an estrogen which is no longer marketed.^{[1] [2] [3]} It is an estrogen ester, specifically the C17β phenylpropionate ester of estradiol.

EPP has been marketed in combination with estradiol benzoate under the brand name Dimenformon Prolongatum in Europe and in combination with estradiol benzoate, testosterone propionate, testosterone phenylpropionate, and testosterone isocaproate under the brand names Mixogen, Estandron Prolongatum, and Lynandron Prolongatum (a balanced mixture of estradiol and testosterone esters) in menopausal hormone therapy.^{[4] [5] [6] [7]} Both of these medication combinations are long-acting injectables indicated in hormone replacement therapy for women in menopause. Dimenformon Prolongatum has also been investigated as a single injection, "morning after" post-coital contraceptive, and is additionally used as a component of hormone replacement therapy for transgender women.

The pharmacokinetics of EPP in combination with estradiol benzoate have been studied.^{[8] [9]}

See also

• List of estrogen esters § Estradiol esters
• Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate
• Estradiol benzoate/estradiol phenylpropionate

Notes and References

1. Book: Index Nominum 2000: International Drug Directory. January 2000. Taylor & Francis. 978-3-88763-075-1. 406–.
2. Book: Garaffa G, Ralph DJ . Female to Male Transsexualism . Mirone V . Clinical Uro-Andrology . https://books.google.com/books?id=1KynBgAAQBAJ&pg=PA17 . 12 February 2015. Springer. 978-3-662-45018-5. 17–.
3. Book: Hager HH, Kern W, List PH, Roth HJ . Oestradiol . Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Ärzte und Medizinalbeamte: Wirkstoffgruppen II Chemikalien und Drogen (A-AL). https://books.google.com/books?id=a2a0BgAAQBAJ&pg=PA157 . 29 July 2013. Springer-Verlag. 978-3-662-25655-8. 157–.
4. Book: Saure A . Die Wechseljahre der Frau. Hormonpräparate, die zur Behandlung der Wechseljahre eingesetzt werden. 1989. 153–164. 10.1007/978-3-0348-6676-7_11. 978-3-7643-1947-2.
5. Web site: MIXOGEN® (Injection) . 2016-06-10 . 2016-05-30 . https://web.archive.org/web/20160530005833/http://home.intekom.com/pharm/donmed/mixogen.html . dead .
6. Book: Pschyrembeln W . Störungen in der Postmenopause . Praktische Gynäkologie: für Studierende und Ärzte. https://books.google.com/books?id=vVaTnHDFzZ0C&pg=PA533. 15 June 2011. Walter de Gruyter. 978-3-11-150424-7. 533–.
7. Book: Rote Liste: Verzeichnis pharmazeutischer Spezialpräparate. 1965. Editio Cantor. Lynandron Prolongatum ® (Organon -> O 70) Zus. 1 Ampulle zu 1 ml: 1 mg Oestradiolbenzoat, 4 mg Oestradiolphenylpropionat, 20 mg Testosteronpropionat, 40 mg Testosteronphenylpropionat, 40 mg Testosteronisocapronat..
8. Rauramo L, Punnonen R, Kaihola LH, Grönroos M . Serum oestrone, oestradiol and oestriol concentrations in castrated women during intramuscular oestradiol valerate and oestradiolbenzoate-oestradiolphenylpropionate therapy . Maturitas . 2 . 1 . 53–58 . January 1980 . 7402086 . 10.1016/0378-5122(80)90060-2 .
9. Rauramo L, Punnonen R, Grönroos M . Serum concentrations of oestrone, oestradiol and oestriol during various oestrogen treatments . Maturitas . 3 . 2 . 183–186 . August 1981 . 7289888 . 10.1016/0378-5122(81)90010-4 .